Table 5.
Study | No of eyes | Type of CSCR treated | Result CRT |
---|---|---|---|
Özmert E, J Ophthalmol. 2016 | 15 | chronic | SRF resolution in 80%, BCVA improvement of 4.2 letters ETDRS |
Scholz P, Eye 2016 | 42 | chronic | CRT reduction in 79% of cases, mean values 445 μm to 297 μm |
Luttrull JK, Retina 2016 | 11 | acute/chronic | SRF resolution in all cases, mean BCVA improvement from 20/37 to 20/24 |
Abd Elhamid, Clin Ophthalmol. 2015 | 15 | acute/chronic | CRT reduction from 389 μm to 263 μm Mean BCVA improvement from 0.67 to 0.85 |
Scholz P, Ophthalmologica 2015 | 38 | chronic, including resistant to PDT | CRT reduction in 74%, mean CRT decrease 115 μm, BCVA improvement by logMAR-0.06 |
Kim JY, Graefes Arch Clin Exp Ophthalmol. 2015 | 10 | chronic and recurrent | Mean BCVA improvement from 0.21 to 0.055 logMAR, mean CRT reduction from 349.2 μm to 250.7 μm |
Yadav NK, Eye 2015 | 15 | chronic | Mean BCVA improvement of one line on Snellen chart, 79% reduction in SRF height |
Malik KJ, Retina 2015 | 11 | acute/chronic | Mean 97 μm decrease of CRT |
Present study | 51 | chronic | SRF resolution in 70.6 % of cases; mean BCVA improvement in logMAR 0.08 |
SRF subretinal fluid, CRT central retinal thickness, BCVA best corrected visual acuity